Mandeville Therapeutics

Mandeville Therapeutics is a Chronic Kidney Disease Therapy Treatment

ActiveBioTechMedicalTherapeutics

Updated: Feb 17, 2026 ·

About

Mandeville Therapeutics is a biotechnology company dedicated to developing novel treatments for chronic kidney disease (CKD). The company focuses on creating small-molecule therapies with the aim of transforming the current therapeutic landscape for this condition. Its research and development efforts are concentrated on addressing the significant medical needs associated with CKD.

Headquartered in Pittsburgh, Pennsylvania, Mandeville Therapeutics operates within the region's biotechnology sector. The company's work involves advancing new therapeutic options to improve patient outcomes for individuals affected by chronic kidney disease.

Recent News & Mentions

Feb 10, 2026FundingMandeville Therapeutics - Seed

Financial History

Mandeville Therapeutics has raised $100K across 1 funding round. Most recently, it raised $100K Seed in February 2026.

Total Raised

$100K

Valuation

N/A

Funding Rounds Raised

Date	Round	Lead Investors	Other Investors
Feb 10, 2026	$100K Seed	AlphaLab

Financial History

Mandeville Therapeutics has raised $100K across 1 funding round.

Total Raised

$100K

Valuation

N/A

Deep Dive

Mandeville Therapeutics is a biotechnology company specializing in the development of therapies for chronic kidney disease (CKD). The organization's core mission is to innovate new treatment modalities that can significantly impact the management and progression of this debilitating condition. Its approach centers on scientific research and the advancement of novel pharmaceutical solutions.

The company's therapeutic strategy involves the development of small-molecule therapies. These compounds are designed to intervene in the biological pathways associated with chronic kidney disease, offering a targeted approach to treatment. Mandeville Therapeutics aims for these small-molecule interventions to provide more effective and transformative options for patients.

Chronic kidney disease affects a substantial global population, representing a significant unmet medical need. Mandeville Therapeutics' focus on CKD underscores its commitment to addressing a major public health challenge through cutting-edge biotechnology research. The company seeks to contribute to a future where CKD patients have access to advanced and life-changing treatments.

Mandeville Therapeutics is based in Pittsburgh, Pennsylvania, establishing its operations within a growing hub for biotechnology and medical innovation. This location supports its research and development activities in the field of biotechnology. The company is actively engaged in the local ecosystem, contributing to the region's scientific and entrepreneurial landscape.

Sources

Frequently Asked Questions

What specific type of therapies does Mandeville Therapeutics develop?

Mandeville Therapeutics develops small-molecule therapies, which are designed to transform the treatment of chronic kidney disease.

What medical condition is the primary focus of Mandeville Therapeutics' research?

The primary medical condition that Mandeville Therapeutics focuses on is chronic kidney disease, for which it is developing new therapeutic approaches.

Where is Mandeville Therapeutics headquartered?

Mandeville Therapeutics is headquartered in Pittsburgh, Pennsylvania, where it conducts its biotechnology research.